Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PF-05231023

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Pharmacological administration of FGF21 analogues has shown robust body weight reduction and lipid profile improvement in both… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2017
Review
2017
In 2016, four studies were published that provided crucial new information on the endocrine actions of the hormone fibroblast… Expand
  • figure 1
Highly Cited
2017
Highly Cited
2017
To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PF‐05231023, a long‐acting fibroblast growth factor… Expand
Highly Cited
2016
Highly Cited
2016
FGF21 plays a central role in energy, lipid, and glucose homeostasis. To characterize the pharmacologic effects of FGF21, we… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Highly Cited
2015
Highly Cited
2015
AIMS The aim of the present study was to evaluate the pharmacokinetics/pharmacodynamics (PK/PD), safety and tolerability of… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
2015
2015
Pharmacological administration of fibroblast growth factor 21 (FGF21) improves metabolic profile in preclinical species and… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2015
2015
PF-05231023, a long-acting fibroblast growth factor 21 (FGF21) analog, was generated by covalently conjugating two engineered… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3